Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer

BACKGROUND: Monoclonal antibodies (mAb) that block programmed death (PD)-1 signaling pathway hold great potential as a novel cancer immunotherapy. Recent evidence suggests that combining with conventional, targeted or other immunotherapies, these mAb can induce synergistic antitumor responses. In th...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Zhiqiang, Wang, Haolin, Meng, Fandong, Li, Jie, Zhang, Shulan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517526/
https://www.ncbi.nlm.nih.gov/pubmed/26219551
http://dx.doi.org/10.1186/s12967-015-0613-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517526/
https://www.ncbi.nlm.nih.gov/pubmed/26219551
http://dx.doi.org/10.1186/s12967-015-0613-y

Ejemplares similares